

News Article downloaded from - <http://www.bioportfolio.com> on Monday, November 23, 2009
Read [GSK Submits TYVERB\(R\)/TYKERB\(R\) \(lapatinib\) for First-Line Treatment of Metastatic Breast Cancer in Europe, US](http://www.bioportfolio.com/news/GSK_Submits_TYVERB(R)/TYKERB(R)_for_First-Line_Treatment_of_Metastatic_Breast_Cancer_in_Europe_US) on BioPortfolio.com
([http://www.bioportfolio.com/news/GSK_Submits_TYVERB\(R\)/TYKERB\(R\)_for.html](http://www.bioportfolio.com/news/GSK_Submits_TYVERB(R)/TYKERB(R)_for_First-Line_Treatment_of_Metastatic_Breast_Cancer_in_Europe_US))

GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US

Wednesday 1st of April 2009 9:00

BioPortfolio no longer holds the full text of this article in PDF form.

[Click Here To Read BioPortfolio's Web Page on GSK Submits TYVERB\(R\)/TYKERB\(R\) \(lapatinib\) for First-Line Treatment of Metastatic Breast Cancer in Europe, US](#)

- [Press Releases for GSK 21 Apr 2009 ... GSK Submits TYVERB\(R\)/TYKERB\(R\) \(lapatinib\) for First-Line Treatment of Metastatic Breast Cancer in Europe, US ...](#)
<http://www.istockanalyst.com/press/GSK...>

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)
Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472
[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.
BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

